Peptide Research: Cagrilintide – Studies, Research Use, and Scientific Background

What is Cagrilintide?

Cagrilintide is a synthetic long-acting amylin analogue designed for research into appetite regulation, weight management, and metabolic disorders. It is studied in laboratory models for its effects on food intake, body weight, and energy balance, primarily through its action on amylin and calcitonin receptors.
For laboratory research use only. Not for human or veterinary use.

Key Scientific Studies

• Weight Management and Appetite Suppression: A 2021 clinical trial published in New England Journal of Medicine found that cagrilintide administration led to significant body weight reduction in research participants with overweight or obesity, as well as decreased appetite.
  Frias et al., 2021
• Synergy with GLP-1 Receptor Agonists: Preclinical and clinical studies indicate that cagrilintide, when combined with GLP-1 agonists such as semaglutide, further enhances weight loss and appetite control in laboratory and human research settings.
  Bagger et al., 2021

Laboratory Research Applications

• Preclinical models of obesity and metabolic syndrome
• Research on appetite regulation and satiety pathways
• Studies of amylin and calcitonin receptor pharmacology
• Combination therapy research with GLP-1 analogues

Mechanism of Action (in Research Context)

Cagrilintide acts as a dual amylin and calcitonin receptor agonist, reducing food intake and supporting weight loss in laboratory models. Its long-acting structure allows for extended pharmacological effects on satiety and metabolic regulation in preclinical studies.

Reference Dosing Schedules from Published Studies

The following dosing protocols have been reported in published laboratory and clinical studies of cagrilintide:

• Common Dose Range (animal studies): 10–100 mcg/kg, administered subcutaneously or intraperitoneally
• Clinical Research Dose: 1.2–4.5 mg once weekly by subcutaneous injection (as reported in human clinical studies)
• Duration: Typically 20–26 weeks in published research protocols